ACE and acute kidney injury: Accordingly, given the lack of consistent benefits on major clinical outcomes and considering the existent evidence [22,30,39–41,75] of adverse effects in terms of hypotension, hyperkalemia, and acute kidney injury, overall recommendations cautioning against the use of combination therapy with an ACE inhibitor and an ARB are still valid.